[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100480319":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":133,"collaborators":30,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":30,"eligibilityCriteria":141,"healthyVolunteers":137,"sex":142,"minAge":143,"maxAge":30,"enrollmentInfo":144,"targetDuration":30,"studyType":147,"phases":148,"briefSummary":150,"conditions":151,"keywords":158,"overallStatus":39,"whyStopped":30,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":172},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with oligometastatic breast cancer","EXPERIMENTAL","Participants with oligometastatic breast cancer with isolated progression after sustained (\\>=6 month) response to systemic therapy. Participants will receive image guided, SBRT to the progressive lesion identified on imaging. Participants will be maintained on their existing line of systemic therapy. Systemic therapy will be held during days of radiation and resume following completion of radiation.",[13],"Radiation: Stereotactic body radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Stereotactic body radiotherapy","SBRT will be initiated as soon as possible, at not beyond 8 weeks of baseline measurements. Recommended dosing is per department standards for oligometastatic disease (ie, 10 Gy x 3 or 7-8 Gy x 5 fractions daily, excluding weekends and departmental holidays)",[9],[21],"SBRT",[23],{"name":24,"affiliation":5,"role":25},"Amy Xu, MD, PhD","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","646-888-6863",null,"xua@mskcc.org",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"Atif Khan, MD","848-225-6334","khana7@mskcc.org",[37,53,64,75,87,98,107,118],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)","RECRUITING","Basking Ridge","New Jersey","10065","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-74.54932,40.70621,{"lat":49,"lon":48},[52],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":30},{"facility":54,"status":39,"city":55,"state":41,"zip":56,"country":43,"countryCode":44,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Memorial Sloan Kettering Monmouth (Limited Protocol Activities)","Middletown","07748",{"type":46,"coordinates":58},[59,60],-74.11709,40.39428,{"lat":60,"lon":59},[63],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":30},{"facility":65,"status":39,"city":66,"state":41,"zip":67,"country":43,"countryCode":44,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Memorial Sloan Kettering Bergen (Limited Protocol Activities)","Montvale","07645",{"type":46,"coordinates":69},[70,71],-74.02292,41.04676,{"lat":71,"lon":70},[74],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":30},{"facility":76,"status":39,"city":77,"state":78,"zip":79,"country":43,"countryCode":44,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Memorial Sloan Kettering Commack (Limited Protocol Activities)","Commack","New York","11725",{"type":46,"coordinates":81},[82,83],-73.29289,40.84288,{"lat":83,"lon":82},[86],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":30},{"facility":88,"status":39,"city":89,"state":78,"zip":90,"country":43,"countryCode":44,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Memorial Sloan Kettering Westchester (Limited Protocol Activities)","Harrison","10604",{"type":46,"coordinates":92},[93,94],-73.71263,40.96899,{"lat":94,"lon":93},[97],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":30},{"facility":99,"status":39,"city":78,"state":78,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)",{"type":46,"coordinates":101},[102,103],-74.00597,40.71427,{"lat":103,"lon":102},[106],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":30},{"facility":108,"status":39,"city":109,"state":78,"zip":110,"country":43,"countryCode":44,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Memorial Sloan Kettering Nassau (Limited Protocol Activities)","Uniondale","11553",{"type":46,"coordinates":112},[113,114],-73.59291,40.70038,{"lat":114,"lon":113},[117],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":30},{"facility":119,"status":120,"city":121,"state":122,"zip":123,"country":43,"countryCode":44,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Lehigh Valley Health Network (Data Collection Only)","NOT_YET_RECRUITING","Allentown","Pennsylvania","18103",{"type":46,"coordinates":125},[126,127],-75.49018,40.60843,{"lat":127,"lon":126},[130],{"name":131,"role":28,"phone":132,"phoneExt":30,"email":30},"Alyson McIntosh, MD","610-402-0700",{"type":134,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100480319","phase-2-a-study-on-adding-precisely-targeted-radiation-therapy-stereotactic-body-radiation-therapy-to-the-usual-treatment-approach-drug-therapy-in-people-with-breast-cancer-100480319",false,"NCT05534438","A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer","Stereotactic Body Radiation Therapy (SBRT) to Extend the Benefit of Systemic Therapy in Patients With Solitary Disease Progression","Inclusion Criteria:\n\n* Age 18 or older\n* Willing and able to provide informed consent\n* Metastatic breast cancer, biopsy proven\n\n  * ER+\u002FHER2-, defined as \\>5% ER+ staining\n  * HER2+ (regardless of ER status), including HER2-low and high expressors\n* History of at least 6 months, sustained response to systemic therapy (clinically or radiographically defined as complete or stable response without progression)\n* Isolated site of disease progression on FDG PET scan\n* Consented to 12-245\n* ECOG performance status 0-1\n\nExclusion Criteria:\n\n* Pregnancy\n* Serious medical comorbidity precluding radiation, including connective tissue disorders\n* Intracranial disease (including previous intracranial involvement)\n* Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.","ALL","18 Years",{"count":145,"type":146},46,"ESTIMATED","INTERVENTIONAL",[149],"PHASE2","The purpose of this study is to see if using Stereotactic Body Radiation Therapy\u002FSBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.",[152,153,154,155,156,157],"Oligometastatic Breast Carcinoma","Breast Cancer","Metastatic Breast Cancer","Metastatic Breast Carcinoma","ER+ Breast Cancer","HER2+ Breast Cancer",[159,160,156,157,154,161,162,5],"oligometastatic breast cancer","breast cancer","Stereotactic Body Radiation Therapy","22-259","2026-04-13",{"date":165,"type":166},"2026-04-16","ACTUAL",{"date":168,"type":166},"2022-09-06",{"date":170,"type":146},"2026-09-06",{"name":5,"class":6},8]